← Back to Clinical Trials
Recruiting Phase 3 NCT05412381

PRP in ACLR to Prevent PTOA

Trial Parameters

Condition Anterior Cruciate Ligament Injuries
Sponsor Hospital for Special Surgery, New York
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 56
Sex ALL
Min Age 14 Years
Max Age 50 Years
Start Date 2022-06-27
Completion 2026-12-31
Interventions
platelet rich plasma (PRP) injectionplacebo saline injection

Brief Summary

The purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in patients with acute ACL injury. This RCT has been powered based on the questionnaire KOOS Jr. but it is considered a 'pilot study' in terms of the lab analysis proposed.

Eligibility Criteria

Inclusion Criteria: * Acute ACL injury within 6 weeks of presentation * Age 14-50 * Male or female * Meniscus injury that can be treated with meniscectomy or repair (the lack of meniscus injury will not exclude patients) Exclusion Criteria: * Prior ACL reconstruction * Prior cartilage repair procedure * Prior meniscus surgery within 12 months * Prior steroid, hyaluronic acid, or PRP injection within 6 months * Other ligament injury requiring repair * Any cartilage lesion requiring repair * Any cartilage lesion greater than grade 2 (partial thickness injury) * History of inflammatory arthritis or joint sepsis * Non English speakers

Related Trials